BioSpace News Archive

Kane Biotech Inc., a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2021 financial results after market close on Thursday, May 27, 2021.

Entera Bio Ltd., a leader in the development of orally delivered large molecule therapeutics, announced financial and operating results for the quarter ended March 31, 2021.

Chiasma, Inc. announced that it will virtually present encore data from its MPOWERED™ Phase 3 clinical trial at the 23rd European Congress of Endocrinology and new data from the MPOWERED trial at the 30th Annual American Association of Clinical Endocrinology Meeting.

TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced the presentation of two abstracts at the upcoming American Society of Clinical Oncology

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will present at the following investor conferences in June: Jefferies Virtual Healthcare Conference Date: Wednesday, June 2 nd at 2:30 p.m. ET

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced the appointment of Sandra Rojas-Caro, M.D., as Chief Medical Officer, effective May 24, 2021. With more than 20 years of drug development experience across all phases of drug development,

Experienced biopharmaceutical executive, John F. Thero, Chief Executive Officer of Amarin Corporation PLC, a commercial-stage cardiovascular company Seasoned biopharmaceutical finance executive, Troy Ignelzi, Chief Financial Officer of Karuna Therapeutics, a clinical-stage neuroscience company Experienced biopharmaceutical executive, Marc de Garidel, former Chief Executive Officer of Corvidia Therapeutics, Chairman and former Chief Executive Officer of Ipsen Group

First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on track for IND-enabling activities in 2022 Multi kinase inhibitor, BTX-A51, to continue in Phase 1 with expansion into solid tumors

Completion of enrollment for the Phase 2b study in osteoarthritis of the knee Clinical data presented at OARSI provides support for osteoarthritis program First patient dosed in the Phase 1/2a study in neuropathic pain